- Home
- ZBRA vs BBIO Comparison
ZBRA vs BBIO Comparison
Compare ZBRA & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBRA | BBIO |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 14.7B |
| IPO Year | 1991 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ZBRA | BBIO |
|---|---|---|
| Price | $255.96 | $72.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 20 |
| Target Price | ★ $340.57 | $77.55 |
| AVG Volume (30 Days) | 569.8K | ★ 1.8M |
| Earning Date | 02-12-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.78 | N/A |
| EPS | ★ 9.93 | N/A |
| Revenue | ★ $5,255,000,000.00 | $353,780,000.00 |
| Revenue This Year | $10.26 | $127.64 |
| Revenue Next Year | $10.00 | $78.38 |
| P/E Ratio | $25.45 | ★ N/A |
| Revenue Growth | 12.87 | ★ 62.46 |
| 52 Week Low | $205.73 | $27.86 |
| 52 Week High | $427.76 | $78.59 |
Technical Indicators
Market Signals| Indicator | ZBRA | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.13 | 51.57 |
| Support Level | $242.64 | $74.47 |
| Resistance Level | $247.25 | $78.59 |
| Average True Range (ATR) | 6.25 | 2.47 |
| MACD | 0.52 | -0.57 |
| Stochastic Oscillator | 61.89 | 38.27 |
Price Performance
Historical ComparisonAbout ZBRA Zebra Technologies Corporation
Zebra Technologies is a leading provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.